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Abstract
Background: The outcome of CMV/HIV co-infection in infants treated early with combined antiretroviral therapy
(cART) in resource-limited settings has not been described.
We aimed to estimate the prevalence and identify factors associated with early CMV infection in HIV-infected and
non-infected infants included in a study in Cameroon, and to compare HIV disease progression and survival after
1 year of early cART, following infants’ CMV status.
Methods: HIV-infected infants followed from birth or from HIV diagnosis before 7 months old and HIV-uninfected
infants born to HIV-infected or uninfected mothers were tested for CMV at a median age of 4.0 months
[Interquartile range (IQR): 3.4–4.9]. Multivariable logistic regression was performed to identify factors associated with
CMV infection. Early cART was offered to HIV-infected infants: mortality, immunological and virological outcomes
were assessed.
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Results: Three hundred and sixty-nine infants were tested. The proportion of infants infected with CMV at baseline
was significantly higher in HIV-infected than in HIV-uninfected groups (58.9% (86/146) vs 30.0% (67/223), p < 0.001). At
baseline, median CMV viral load was higher in HIV-infected (3.7 log copies/ml [IQR; 3.1–4.3]) than in HIV-uninfected
infants (2.8 log copies [IQR; 2.1–3.4], p < 0.001). cART was initiated in 90% of HIV-infected infants (132/146) at a
median age of 4.0 months (IQR; 3.2–5.9); in this sub-group CMV infection was independently associated with being
followed from the time of HIV diagnosis rather than from birth (aOR = 3.1, 95%CI [1.2–8.0]), born to a non-single
mother (aOR = 3.4[1.4–8.1]), and breastfeeding (aOR = 7.3 [2.7–19.4]). HIV-infected infants were retested after a
median of 7.1 months [4.8–9.5]: CMV was undetectable in 37 of the 61 (60.7%) initially CMV-infected cases and
became detectable in 8 of the 38 (21.1%) initially CMV-negative cases. After 1 year of cART, the probability of death
(0.185 vs 0.203; p = 0.75), the proportion of cases with HIV RNA viral load <400 copies/ml (75.5% vs 61.5%; p = 0.17)
and the mean CD4 percentage increase (10.97% vs 6.88%; p = 0.15) did not differ between CMV+ and CMV- infants.
Conclusions: We observed a high prevalence of CMV infection among HIV-infected infants. Early initiation of cART
may have limited the negative impact of CMV even in the absence of specific anti-CMV treatment.
Keywords: Cytomegalovirus, Human Immunodeficiency Virus, Co-infection, Early treated HIV-infected infants
Background
African children infected with human cytomegalovirus
(CMV) usually acquire it during the first year of life [1]. It is
one of the major congenital infections worldwide and a sig-
nificant opportunistic pathogen for immune-compromised
individuals [2, 3]. In most immunocompetent infants, CMV
infection is asymptomatic; however, HIV-infected children
are at risk of developing CMV disease [4]. Several studies
report that HIV-infected newborns are at higher risk of
symptomatic congenital CMV infection than uninfected
newborns. CMV may act as a cofactor for HIV disease pro-
gression, and the risk of infant mortality is increased in HIV/
CMVco-infected infants [5–7].
The consequences of prenatal antiretroviral (ARV)
prophylaxis on CMV transmission from HIV-infected
women to their babies and of highly active antiretroviral
therapy (HAART) to halt the progression of CMV disease
are still unclear. In the French perinatal cohort, the incidence
of vertical CMV transmission from HIV-infected mothers
declined with the introduction of HAART [7]. Nevertheless,
no significant decrease was observed in the prevalence of
congenital CMV infection in children born to HIV-infected
mothers receiving prenatal antiretroviral therapy in a recent
study, [8]. Little is known about congenital CMV infection
among HIV-exposed infants in sub-Saharan Africa [9–11].
We estimated the prevalence of early CMV infection in
HIV-infected and HIV-uninfected infants included before
7 months of age in three urban hospitals in Cameroon. We
identified risk factors and compared disease progression
and survival during the first year after early cART following
CMV status.
Methods
The ANRS 12140—Pediacam study
The ANRS 12140-Pediacam is an ongoing prospective ob-
servational cohort coordinated at the Centre Pasteur of
Cameroon, designed to assess the feasibility of early cART
in HIV-infected infants in three referral hospitals: the
Mother and Child Center of the Chantal Biya Foundation
(MCC-CBF), the Hospital Center Essos (HCE) both in
Yaounde; and Laquintinie Hospital (LH) in Douala. Infant
inclusion into the Pediacam was conducted in two con-
secutive phases. The first phase, planned from birth to
14 weeks, included all infants born live to HIV-infected
mothers and an equivalent number of infants born to HIV-
uninfected mothers matched individually on gender and
recruitment site. The newborn pairs were followed, tested
for HIV (where needed) and given routine vaccinations.
All identified HIV-infected infants (Group 1i) and
selected controls of uninfected infants followed from
birth, born to HIV-infected mothers (Group 1ni) or to
HIV-uninfected mothers (Group 2ni) were included in
the second phase that was planned for children from
14 weeks to 2 years old. Inclusion into the second phase
was also offered to HIV-infected children not included
from birth but aged less than 7 months at diagnosis of
HIV infection (Group 3i). After inclusion in the second
phase, infants underwent biological assessment including
CMV testing and HIV-infected infants were offered
systematic cART according to the Cameroonian guide-
lines at the time of this study. First-line treatment
was zidovudine (or stavudine for infants with anemia)
and lamivudine associated with lopinavir/ritonavir if
nevirapine (NVP) had been used for the Prevention of
mother-to-child transmission of HIV (PMTCT), or with
NVP if it had not been used for PMTCT. Biological ana-
lyses (including whole blood counts, CD4 T-lymphocyte
cell counts, liver function tests, amylases, blood sugar
levels, tuberculosis and malaria) were subsequently
planned every 3 months or every 6 months until 2 years
of age for HIV-infected and HIV-uninfected infants,
respectively.
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Study population
All the infants participating in the ANRS 12140-Pediacam
prospective study and screened for CMV infection at
inclusion into the second phase were considered in the
present analysis.
From November 2007 to October 2013, a total of 611 in-
fants were included in the second phase of the ANRS
12140-Pediacam study: 69 were HIV-infected followed
from birth (Group 1i); 141 were HIV-infected not followed
from birth and diagnosed before age 7 months (Group 3i);
205 were HIV-uninfected born to HIV-infected mothers
(Group 1ni); and 196 were HIV-uninfected born to HIV-
uninfected mothers (Group 2ni) (Fig. 1). Of these infants,
242 were not screened for CMV, including 140 (57.9%) in
Douala where there was no system in place to collect and
transfer samples to Centre Pasteur of Cameroon in
Yaounde for analysis, and 102 in Yaounde.
Outcomes definition and covariates
The main outcome was the CMV infection status de-
fined as the presence or absence of any CMV genomes
in the blood at inclusion into the second phase of the
ANRS 12140-Pediacam study. The CMV test was re-
peated at various time points during the first year of
antiretroviral treatment to assess disease progression.
Secondary outcomes were measured during the year
following initiation of antiretroviral therapy: Kaplan-
Meier probability of death, viral suppression defined as
viral load <400 copies/mL at two consecutives routine
tri-monthly visits, and mean difference in CD4 percent-
age difference between inclusion and the last follow-up
measure.
Risk factors of CMV infection recorded included those
that were related to infant characteristics both at birth
and at inclusion, maternal characteristics and socio-
economic status, quality of antenatal care and obstetrical
context at delivery.
Cytomegalovirus diagnosis and quantification
CMV testing was planned at inclusion into the second
phase and every 3 or 6 months according to infant HIV
status (see above). At each time point, 200 μL of whole
blood was drawn and stored at -80 °C for CMV analysis.
Viral nucleic acids (DNA) were extracted using the
QIAamp DNA mini kit (QIAGEN®, Hilden, Germany)
and eluted from the columns with 200 μL of DNAse/
RNAse free water. Aliquots of 5 μL were used for PCR.
Primers and probe for the real-time PCR quantification
corresponded to the UL 123 exon 4 gene as previously
described [12, 13]. A plasmid containing the amplified
sequence of strain AD 169 (Tebu France) was used as an
external standard. For each batch, serial dilutions of
plasmid (range, 50 to 500,000 copies) were amplified to
establish a standard curve and allow the quantification
of CMV in clinical samples. Appropriate negative and
positive controls were included in each run. The results
are reported as the number of CMV genome copies/mL
of whole blood.
Fig. 1 Study population and description of infant age at CMV screening in the phase 2 of the ANRS-PEDIACAM study, Cameroon, 2007–2012
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Statistical analysis
Maternal socio-economic and demographic data, ante-
natal care and obstetrical context, and infant characteris-
tics are described using proportions for categorical
variables, or medians and interquartile ranges for continu-
ous variables. Bivariable analysis was used to study associ-
ations between baseline factors and CMV infection, both
overall and according to infant HIV status. Multivariable
logistic regression models were used to identify independ-
ent factors, including initially non-collinear covariates as-
sociated with CMV infection (as a dependent variable) if
the p-value was ≤ 0.25 in the bivariable analysis. The final
model was obtained by successively removing variables
not associated at a p-value <0.05 and only if the odds
ratios for the remaining variables were unchanged and
taking interactions into account. Known risk factors
(breastfeeding) and sampling variables (infant group) were
maintained in the final model.
Among HIV-infected children treated with cART, the
relation between CMV status and various outcomes of
HIV disease progression, censored at 52 +/-6 weeks after
ART initiation, was studied. The risk of death or death/
loss to follow up in the two CMV status groups was esti-
mated by Kaplan-Meier survival analysis using log rank
test to test for significance. The proportion of infants
with adequate viral load suppression and mean differ-
ence of CD4 percentage were compared between the
two groups using Fisher’s exact tests and Student’s t test,
respectively. All statistical analyses were performed using
R 2.15 software.
Ethical considerations
The ANRS 12140-PEDIACAM study received ethical ap-
proval in Cameroon from the National Ethics Committee.
Administrative authorization was obtained from the
Ministry of Public Health before the start of the study.
Written informed consent from one of the parents or
guardians was required for inclusion into either phase 1
or phase 2 of the ANRS-Pediacam study.
Results
Characteristics of the study population by infant group
Of the 611 infants included in the second phase of
Pediacam, 369 were tested for CMV. There were no signifi-
cant differences in the following characteristics between in-
fants tested and not tested for CMV in the Yaounde sites:
feeding practice, recruitment site, maternal marital status,
and infant age at inclusion. However, the proportion of un-
infected infants born to HIV-uninfected mothers was
higher in “the not screened” than “screened” for CMV
group (47.1% (48/102) vs 29.0% (107/369); p < 0.001).
Table 1 reports and compares the characteristics of the 369
infants according to HIV status and mode of inclusion: 41
HIV-infected infants followed from birth (group 1i), 105
HIV-infected infants diagnosed later in life before age of
7 months (group 3i), 116 HIV-uninfected infants born to
HIV-infected mothers (group 1ni), and 107 HIV-uninfected
infants born to HIV-uninfected mothers (group 2ni). These
groups were significantly different when maternal educa-
tion level and breastfeeding were considered. The propor-
tion of breastfed infant was 99.1% among HIV- infants
born to HIV uninfected mothers, 58.7% among HIV+ in-
fants not followed from birth but diagnosed before age of
7 months, 27.5% among HIV+ infants followed from birth,
and 12.9% among HIV- infants born to HIV+ mothers.
The overall median age at CMV screening was
4.0 months [Interquartile range (IQR): 3.4–4.9], and was
2.6 months [IQR: 2.2–3.4] for HIV+ infants followed
from birth to 4.3 months [IQR: 3.2–5.8] for HIV+ infants
not followed from birth (Fig. 1).
Prevalence and factors associated with CMV infection at
baseline
The overall CMV prevalence was 41.5% (95% CI: 36.4–46.7):
15.5% (9.5–23.4) for HIV- infants born to HIV+ mothers,
34.1% (20.1–50.6) for HIV+ infants followed from birth,
45.8% (36.1–55.7) for HIV- infants born to HIV- mothers
and 68.6% (58.8–77.3) for HIV+ infants not followed from
birth but diagnosed before age of 7 months (p < 0.01)
(Table 1). The prevalence of CMV infection and the
median CMV viral load were both significantly higher
among HIV+ (58.9%; 3.7 log copies/mL [IQR: 2.5–3.9])
than HIV- (30.0%; 2.8 log copies [IQR; 2.1–3.4]) infants.
In the HIV+ groups of infants, breastfeeding was more
prevalent among infants who were CMV+ than CMV-
(70.6% vs 20.3%; p < 0.001); CMV+ infants compared to
CMV- infants were more underweight (50.0% vs 28.3%
with weight-for-age Z scores < -2SD; p = 0.01); more sick
(55.8% vs 26.7% with HIV clinical stage 3 or 4; p < 0.001);
and more immunosuppressed (74.4% vs 47.5% with lym-
phocytes TCD4 < 25%; p = 0.002) respectively.
Significant differences were observed when comparing
CMV-infected infants, who were exposed but uninfected
with HIV versus those who were unexposed and uninfected
with HIV in the following characteristics: female gender
(83.3% vs 49%, p = 0.02), proportion of mothers who
attended higher education (22.2% vs 36.7%, p < 0.01) and
proportion of breastfed infants (38.9% vs 100%, p < 0.01).
Apart from gender, the same differences were observed
between the two groups among the CMV-uninfected
group (Table 2).
Table 3 shows in bivariable analysis that among HIV+
infants, CMV infection was associated with: infant inclu-
sion group (frequent among HIV+ infants included later
but before 7 months); recruitment site (being less frequent
in the Essos Hospital Center than at the MCC-CBF);
married or cohabiting maternal status; and history of
breastfeeding. Infants screened for CMV after 4 months
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more likely to be CMV infected than those screened at a
younger age. All these associations, except age at CMV
screening, remained significant and of the same magni-
tude in multivariable logistic regression analysis. Inclusion
group and breastfeeding act as confounders of the relation
between age at CMV screening and CMV infection. No
interaction was identified between these factors or with
other factors included in the multivariable analysis.
None of the surrogates of economic status (water sup-
ply at home, presence of a functional fridge at home,
electricity at home, professional activity of the mother
and maternal level of education) listed in Table 3 was
associated with CMV infection in either bi or multivari-
able analysis.
Relation between CMV infection and various disease
outcomes after 1 year of early cART in HIV-infected
infants
Among the 132 HIV-infected infants who initiated cART,
58.3% (n = 77) had CMV co-infection. Other than con-
tinuation of the cART, no specific anti-CMV treatment
was given and no major clinical event was recorded. Over-
all, 99 HIV infected infants (61 CMV+ and 38 CMV-) were
retested for CMV after a median duration of cART of
7.1 months (range [4.8–9.5], similar in both groups). The
mean number of CMV tests was 2 (range [1–4]). CMV
was undetectable on retest in 37 (60.7%) of the 61 initially
HIV+CMV+ infants. CMV was detected on retest in
8 (21.1%) of the 38 initially HIV+CMV- infants.
The proportion of infants not followed from birth
was higher in CMV+ than CMV- group (81.8% vs
56.4%; p = 0.001). cART was initiated later in CMV+
infants than CMV- infants (median age of 4.7 months,
IQR: 3.5–6.2 vs 3.6 months, IQR: 2.8–4.8; p = 0.03).
Kaplan-Meier estimates of probability of death after
1 year of cART treatment did not differ significantly
between CMV+ HIV+ and CMV- HIV+ infants [18.5%,
95% CI: 11.4–29.2 vs 20.3, 95% CI: 11.8–33.7]; log rank
test, p = 0.75). Taking into consideration age at cART initi-
ation (<4 months (early) and ≥4 months (late)), the sur-
vival rate were similar for HIV/CMV co-infected treated
early [0.129, 95% CI: 0.050–0.308], HIV/CMV co-infected
treated later [0.225, 95% CI: 0.128–0.378], HIV infected/
CMV uninfected treated early [0.249, 95% CI: 0.138–
0.424], and HIV infected/CMV uninfected treated later
[0.111, 95% CI: 0.030–0.376] (log rank test, p = 0.45)
groups. This was also true of death/loss to follow up as
composite outcomes (p = 0.38). The proportion of cases
with adequate HIV RNA viral suppression was similar in
HIV-CMV co-infected and HIV infected groups (75.5% vs
61.5%; p = 0.17). The mean difference in CD4 percentage
(change between initiation of cART and the last follow up)
was similar CMV+ and CMV- groups (10.97%, standard
deviation (SD): 13.66% vs 6.88%; SD: 15.25%; p = 0.15).
Table 2 Comparison of characteristics between HIV-exposed uninfected and HIV-unexposed-uninfected infants according to CMV
status at inclusion into phase 2 of the ANRS 12140-Pediacam study, 2007–2013, Cameroon
CMV-infected infants CMV-uninfected infants
HIV-exposed uninfected HIV-unexposed-uninfected HIV-exposed uninfected HIV-unexposed-uninfected
N % (n) N % (n) p-value* N % (n) N % (n) p-value*
Study site: Essos Hospital Center 18 33.3 (6) 49 42.9 (21) 0.67 98 36.7 (36) 58 37.9 (22) 1.00
Gender: Female 18 83.3 (15) 49 49.0 (24) 0.02 98 46.9 (46) 58 51.7 (30) 0.68
Marital status: Alone (single
or divorced or widow)
18 22.2 (4) 49 34.7 (17) 0.50 98 36.7 (36) 58 32.8 (19) 0.74
Electricity supply at home: Yes 18 100.0 (18) 48 97.9 (47) 1.00 94 98.9 (93) 57 100 (57) 1.00
Maternal level of education:
Higher education
18 22.2 (4) 49 36.7 (18) <0.01 96 25.0 (24) 58 53.4 (31) <0.01
Maternal age at inclusion:
> = 25 years
18 77.8 (14) 49 69.4 (34) 0.71 97 79.4 (77) 58 81 (47) 0.97
Professional activity of the
mother: Paid
17 58.8 (10) 49 42.9 (21) 0.39 96 50.0 (48) 58 44.8 (26) 0.65
Mode of delivery: Cesarean section 18 11.1 (2) 49 10.2 (5) 1.00 98 12.2 (12) 58 12.1 (7) 1.00
Breastfeeding: Yes 18 38.9 (7) 49 100 (49) <0.01 98 8.2 (8) 58 98.3 (57) <0.01
Prematurity: <37 weeks 18 16.7 (3) 49 10.2 (5) 0.67 98 3.1 (3) 58 13.8 (8) 0.02
Hemoglobin level: < 9 g/dl 18 5.6 (1) 49 4.1 (2) 1.00 98 3.1 (3) 58 6.9 (4) 0.43
Age at CMV screening:
> = 4 months
18 38.9 (7) 49 46.9 (23) 0.76 98 64.3 (63) 58 50.0 (29) 0.11
T CD4 lymphocytes : < 25% 18 11.1 (2) 49 12.2 (6) 1.00 96 3.1 (3) 58 10.3 (6) 0.08
Z-score weight for age: ≤2 SD 18 0.0 (0) 49 2.0 (1) 1.00 98 1.0 (1) 58 0.0 (0) 1.00
Hospitalization at or before inclusion: Yes 18 0.0 (0) 49 4.1 (2) 1.00 98 3.1 (3) 58 1.7 (1) 1.00
*p-value based on Fisher’s exact test
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Table 3 Factors associated with CMV infection in HIV-infected infants enrolled into phase 2 of the ANRS-PEDIACAM study, Cameroon,






% (n) 58.6 (86) cOR (95% CI) p aOR (95% CI) p
HIV infected group in Pediacam (n = 146)
Identified during first week of life 41 34.1 (14) 1 1
Identified later at diagnosis before 7 months of age 105 68.6 (72) 4.2 (1.8–9.8) <.01 2.9 (1.0–7.8) 0.04
Recruitment site (n = 146)
MCC-CBF 95 66.3 (63) 1 1
EHC 51 45.1 (23) 0.4 (0.2–0.9) 0.02 0.4 (0.2–0.9) 0.03
Gender (n = 146)
Female 81 55.6 (45) 1
Male 65 63.1 (41) 1.4 (0.7–2.8) 0.45
Mode of delivery (n = 143)
Vaginal 140 59.3 (83) 1
Cesarean 3 0.0 (0) 0.0 (0.0–1.7) 0.07
Age at CMV screening (n = 146)
< 4 months 82 48.8 (40) 1 1
> =4 months 64 71.9 (46) 2.7 (1.3–5.7) <.01 1.3 (0.5–3.2) 0.62
Feeding practice (n = 144)
No breastfeeding 72 34.7 (25) 1 1
Any history of breastfeeding 72 83.3 (60) 9.2 (4.0–22.6) <.01 6.7 (2.8–15.9) <.01
Water supply at home (n = 139)
Yes 61 60.7 (37) 1
No 78 56.4 (44) 0.8 (0.4–1.8) 0.74
Existence of a functional fridge at home(n = 137)
Yes 53 60.4 (32) 1
No 84 58.3 (49) 0.9 (0.4–2.0) 0.95
Electricity supply at home (n = 139)
Yes 117 56.4 (66) 1
No 22 68.2 (15) 1.7 (0.6–5.2) 0.43
Professional activity of the mother (n = 143)
Housewife/student/unemployed 93 63.4 (59) 1 1
Paid activity 50 52.0 (26) 0.6 (0.3–1.3) 0.25 0.7 (0.3–1.6) 0.33
Maternal level of education (n = 144)
Higher education 8 37.5 (3) 1 1
Secondary education 90 55.6 (50) 2.1 (0.4–14.1) 0.13 1.2 (0.2–6.6) 0.96
None or primary education 46 69.6 (32) 3.7 (0.6–27.2) 1.3 (0.2–8.4)
Maternal marital status (n = 145)
Single/divorced/widow 54 42.6 (23) 1 1
Married/cohabiting 91 68.1 (62) 2.9 (1.4–6.1) <.01 3.4 (1.4–8.2) <.01
Maternal age at inclusion (n = 144)
> = 25 years 102 55.9 (57) 1
< 25 years 42 64.3 (27) 1.4 (0.6–3.2) 0.46
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Discussion
Little is known about the prevalence of early CMV infec-
tions according to the HIV status of infants in resource-
limited settings and even less about its potential role in
HIV progression in infants treated early with cART. We
compared the prevalence of CMV infection in HIV-
infected and -uninfected infants born to HIV-infected
mothers and a control group of infants born to HIV-
negative mothers, all in an urban area of Cameroon. We
also report the first comparison of the prognosis of HIV
infection during first year after early cART initiation be-
tween HIV+ infants with and without CMV co-infection.
Consistent with other studies, we observed that CMV
infection prevalence was higher among HIV-infected
than non-infected infants [6, 9, 14]. One study showed a
higher prevalence of CMV at birth in Kenyan HIV-
infected than HIV-exposed uninfected infants but did
not find any difference by 3 months of age [9]. In an-
other study, CMV prevalence was similar at birth but
significantly different by 6 months [6]. CMV viremia
peaks at 3–4 months of age [15], indicating that direct
CMV diagnostic testing could be particularly sensitive at
this age. Note that most infants in sub-Saharan Africa
are already infected with CMV by 1 year of age [1].
We report here that CMV was associated with breast-
feeding. This was the only single factor independently as-
sociated with CMV infection among HIV-uninfected
infants (born to HIV-infected or HIV-uninfected mothers,
data not shown). In Cameroon, 98% of children under
6 months old are breastfed, either getting breast milk ex-
clusively or in mixed feeding [16]. CMV can be shed into
breast milk and infects breastfeeding children [17]. CMV
shedding into breast milk has been detected as early as
the first week after delivery and peaks between 3 to
5 weeks after delivery [18].
Most breastfed infants of HIV-infected mothers in
resource-limited settings are infected with CMV by
24 weeks of age [19]. The two groups in our study with
high proportions of breastfed infants (HIV- infants born to
uninfected mothers and HIV+ infants not followed from
birth but diagnosed at an age <7 months) also had high
prevalence of CMV infection (45.8 and 68.6% CMV infec-
tion, respectively). This suggests a postnatal transmission of
CMV through breast milk. Surprisingly, a recent study did
not find an association between breastfeeding and CMV
infection in infants [11], but this may have been due, in
part, to the limited number of CMV-infected infants they
included.
Non-single marital status of the mother was also asso-
ciated with a higher risk of CMV infection. Frequent
sexual exposure, as part of the relationship of a couple
may increase the risk of maternal infection and re-
infection with CMV and subsequently its transmission to
the newborn. Very different observations have also been
reported [20, 21], where CMV infection was more frequent
among children born to young and unmarried women.
We found no evidence that CMV infection was associ-
ated with the lack of PMTCT prophylaxis in mothers of
HIV-infected infants. Similarly, Manicklal and colleagues
did not find any relationship between ARV prophylaxis
and congenital CMV infection in HIV-infected infants
[11]. However other studies have suggested that there is an
effect of ARV prophylaxis on CMV infection [7, 22, 23],
cART reduces serological biomarkers of inflammation and
immune activation [24, 25]. ARV could impede CMV re-
activation in HIV-infected pregnant women and thereby
reduce the possibility of CMV transmission to infants born
to mothers who took prophylactic regimens. The differ-
ence observed in our study could be explained by the fact
that we carried out our CMV analyses starting at a median
age of 4 months; consequently we could not distinctively
identify congenital infections and therefore could not es-
tablish the link between prophylactic cART during preg-
nancy and congenital CMV infections. Bivariable analysis
showed that among HIV+ infants, CMV infection was
associated with: infant inclusion group; recruitment site,
married or cohabiting maternal status, history of breast-
feeding and age at CMV screening. All these associations,
except age at CMV screening, remained significant and of
the same magnitude in multivariable logistic regression
analysis. Though the identification and inclusion of infants
of group 3i (n = 105) were in average done later than all
other groups, they were in details not all diagnosed at
7 months as 47 were diagnosed at less 4 months and 58 at
4 months or later. In contrast, infants of group 1i were
mostly diagnosed at less than 4 months. Only 6 out of 41
were diagnosed at 4 months or later. Bringing these two
groups of HIV infected infants together probably had an
Table 3 Factors associated with CMV infection in HIV-infected infants enrolled into phase 2 of the ANRS-PEDIACAM study, Cameroon,
2007–2013 (bivariable and multivariable logistic regression analysis) (Continued)
HIV-infected mothers’ ART status (n = 141)
HAART started before or during pregnancy 14 57.1 (8) 1
ART prophylaxis 48 50.0 (24) 0.8 (0.2–2.9) 0.27
Not treated 79 64.6 (51) 1.4 (0.4–5.0)
The variable “Mode of delivery” was not included in the multivariable analysis because of the small number of Cesareans
MCC-CBF Mother and Child Center of the Chantal Biya Foundation; EHC Essos Hospital Center; cOR Crude Odds ratio; aOR adjusted Odds Ratio; CI Confidence Interval
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impact on the effect age at CMV screening could have with
CMV infection in multivariable analyses.
Among HIV-infected infants, those with CMV co-
infections were mostly immunosuppressed, showed poorer
growth, and had more advanced disease. A rapid progres-
sion of HIV disease in the presence of CMV co-infection
has been described [5, 6, 26–28]. Kovacs et al. observed
that infants with both HIV and CMV infections were more
likely than those with HIV infection alone to have class C
symptoms (severe immune suppression), to have died by
or to have HIV-1 associated encephalopathy by 18 months
[6]. Therefore, we considered in our analyses that clinical
signs associated with CMV infection in infants were conse-
quences rather than causes of the infection and thus these
signs were not included in the multivariable analysis to
identify independent risk factors associated with CMV.
We compared the two groups of HIV-infected infants
(CMV infected and CMV uninfected) 1 year after initi-
ation of cART. This subgroup of HIV infected infants
(CMV+ and CMV-) under cART was particularly stud-
ied in line with the objective of Pediacam which was set
up to study all factors that could be related with early
treatment of HIV in resource limited setting like
Cameroon. Normally, CMV infection is not a major
problem in HIV-uninfected children, as most of them re-
main asymptomatic. However, CMV has been described
to have a negative impact in disease progression in HIV-
infected infants. In resource limited settings CMV treat-
ment is not always available and even when available
could be very toxic. Here, we sought to know if early
cART could reduce HIV disease progression and/or im-
prove survival in these children. These two groups did not
differ significantly regarding the probability of death, com-
posite outcomes (death and lost to follow-up), adequate
viral suppression and mean change in CD4 percentage
since cART initiation. This is consistent with early cART
having counterbalanced the potential negative role of
CMV/HIV co-infections through immune restoration and
control of HIV replication [29]. O’Sullivan observed that
adult patients (mean age, 38 years) who were HIV/CMV
co-infected and treated with cART with no specific anti-
CMV therapy showed a significant drop in CMV viral load
[30]: after 1 year, cART was associated with the complete
suppression of CMV viremia in all patients who returned
for follow-up (23 of 38). We observed no such effect in
HIV/CMV co-infected infants on cART. However, 21.1%
(8/38) of early treated HIV-infected infants who were
CMV negative at inclusion in Pediacam (before cART)
presented subsequent positive tests. This may correspond
to recent infection, common in HIV-uninfected infants.
The strength of this study is the inclusion of four
groups of infants based on their HIV infection and/or
exposure status; all were recruited at the same sites the
same time frame, and were followed in a similar manner.
However, there are also some limitations. The preva-
lence estimates cannot be generalized to other regions
or rural areas in Cameroon, as all the mothers were liv-
ing in urban areas of central Cameroon. Blood samples
were not collected immediately after delivery and for this
reason it was not possible to identify in-utero transmis-
sions of CMV. Also, 20% of the infants were not tested
for CMV on inclusion into phase 2, and their character-
istics did not differ from those tested. According to these
observations, we hypothesized that this group of CMV
screened infants participating in this study could be
representative of the study population. However there
was a higher proportion of non-tested infants among
HIV-uninfected infants born to HIV-uninfected mothers.
Consequently, any selection bias should be limited to re-
sults concerning the HIV-infected group.
Conclusion
We observed a high prevalence of CMV infection among
HIV-infected infants with associated breastfeeding exacer-
bating this prevalence. However early initiation of cART
was shown to limit the negative impact of CMV on HIV
disease progression in CMV/HIV co- infected infants even
in the absence of anti-CMV specific treatment. This study
underscores the benefits of early cART in the case of
CMV/HIV coinfection and further reinforces the recom-
mendations to offer early antiretroviral therapy to all HIV
infected infants.
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